Heterogeneity in Primary Colorectal Cancer and its Corresponding Metastases: A Potential Reason of EGFR-Targeted Therapy Failure?

被引：0

作者：

Li, Zhongqi ^{[1
]}

Jin, Ketao ^{[1
,2
]}

Lan, Huanrong ^{[3
]}

Teng, Lisong ^{[1
]}

机构：

[1] Zhejiang Univ, Affiliated Hosp 1, Dept Surg Oncol, Coll Med, Hangzhou 310003, Zhejiang, Peoples R China

[2] Wenzhou Med Coll, Affiliated Zhuji Hosp, Dept Surg, Zhuji, Zhejiang, Peoples R China

[3] Wenzhou Med Coll, Affiliated Zhuji Hosp, Dept Gynecol & Obstet, Zhuji, Zhejiang, Peoples R China

来源：

HEPATO-GASTROENTEROLOGY | 2011年 / 58卷 / 106期

关键词：

Colorectal cancer; Epidermal growth factor receptor; Heterogeneity; Targeted therapy; GROWTH-FACTOR-RECEPTOR; CETUXIMAB PLUS IRINOTECAN; PROGRESSION-FREE-SURVIVAL; K-RAS MUTATIONS; KRAS MUTATIONS; P53; MUTATIONS; INTRATUMOR HETEROGENEITY; PIK3CA MUTATIONS; PRIMARY TUMORS; HUMAN BREAST;

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Epidermal growth factor receptor (EGFR)targeted therapy represents an important approach in metastatic colorectal cancer (CRC) therapy. However, a number of CRC patients show intrinsic or acquired resistance to EGFR-targeted therapy. EGFR antibody therapy is established in CRC patients with wild-type KRAS. However, up to half of these patients do not respond to this therapy. This phenomenon implied some potential mechanisms of resistance to EGFR inhibitors might exist. One of the potential reasons to explain this phenomenon is heterogeneity of CRC. The heterogeneity of CRC has been well described at the morphological, molecular and genomic levels. This review discussed the potential relationship of heterogeneity, including intratumor heterogeneity of CRC and heterogeneity in primary CRC and its corresponding metastases, to EGFR-targeted therapy failure.

引用

页码：411 / 416

页数：6

共 50 条

[41] EGFR-Based Targeted Therapy for Colorectal Cancer-Promises and Challenges [J].

Janani, Balakarthikeyan ;

Vijayakumar, Mayakrishnan ;

Priya, Kannappan ;

Kim, Jin Hee ;

Prabakaran, D. S. ;

Shahid, Mohammad ;

Al-Ghamdi, Sameer ;

Alsaidan, Mohammed ;

Othman Bahakim, Nasraddin ;

Hassan Abdelzaher, Mohammad ;

Ramesh, Thiyagarajan .

VACCINES, 2022, 10 (04)

[42] Prevalence and Heterogeneity of KRAS, BRAF, and PIK3CA Mutations in Primary Colorectal Adenocarcinomas and Their Corresponding Metastases [J].

Baldus, Stephan E. ;

Schaefer, Karl-L. ;

Engers, Rainer ;

Hartleb, Dinah ;

Stoecklein, Nikolas H. ;

Gabbert, Helmut E. .

CLINICAL CANCER RESEARCH, 2010, 16 (03) :790-799

[43] Broad Detection of Alterations Predicted to Confer Lack of Benefit From EGFR Antibodies or Sensitivity to Targeted Therapy in Advanced Colorectal Cancer [J].

Rankin, Andrew ;

Klempner, Samuel J. ;

Erlich, Rachel ;

Sun, James X. ;

Grothey, Axel ;

Fakih, Marwan ;

George, Thomas J., Jr. ;

Lee, Jeeyun ;

Ross, Jeffrey S. ;

Stephens, Philip J. ;

Miller, Vincent A. ;

Ali, Siraj M. ;

Schrock, Alexa B. .

ONCOLOGIST, 2016, 21 (11) :1306-1314

[44] Drug insight: panitumumab, a human EGFR-targeted monoclonal antibody with promising clinical activity in colorectal cancer [J].

Mano, Max ;

Humblet, Yves .

NATURE CLINICAL PRACTICE ONCOLOGY, 2008, 5 (07) :415-425

[45] Integrated molecular dissection of the epidermal growth factor receptor (EFGR) oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer [J].

Sartore-Bianchi, Andrea ;

Bencardino, Katia ;

Di Nicolantonio, Federica ;

Pozzi, Federico ;

Funaioli, Chiara ;

Gambi, Valentina ;

Arena, Sabrina ;

Martini, Miriam ;

Lamba, Simona ;

Cassingena, Andrea ;

Schiavo, Roberta ;

Bardelli, Alberto ;

Siena, Salvatore .

TARGETED ONCOLOGY, 2010, 5 (01) :19-28

[46] MGMT promoter methylation status in brain metastases from colorectal cancer and corresponding primary tumors [J].

De Maglio, Giovanna ;

Casagrande, Mariaelena ;

Guardascione, Michela ;

Fontanella, Caterina ;

Lutrino, Stefania Eufemia ;

Rihawi, Karim ;

Pisa, Federica Edith ;

Tuniz, Francesco ;

Fasola, Gianpiero ;

Pizzolitto, Stefano ;

Aprile, Giuseppe .

FUTURE ONCOLOGY, 2015, 11 (08) :1201-1209

[47] Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer [J].

Russo, Mariangela ;

Siravegna, Giulia ;

Blaszkowsky, Lawrence S. ;

Corti, Giorgio ;

Crisafulli, Giovanni ;

Ahronian, Leanne G. ;

Mussolin, Benedetta ;

Kwak, Eunice L. ;

Buscarino, Michela ;

Lazzari, Luca ;

Valtorta, Emanuele ;

Truini, Mauro ;

Jessop, Nicholas A. ;

Robinson, Hayley E. ;

Hong, Theodore S. ;

Mino-Kenudson, Mari ;

Di Nicolantonio, Federica ;

Thabet, Ashraf ;

Sartore-Bianchi, Andrea ;

Siena, Salvatore ;

Iafrate, A. John ;

Bardelli, Alberto ;

Corcoran, Ryan B. .

CANCER DISCOVERY, 2016, 6 (02) :147-153

[48] Epidermal growth factor receptor (EGFR) mRNA levels and protein expression levels in primary colorectal cancer and corresponding liver metastases [J].

Kuramochi, Hidekazu ;

Hayashi, Kazuhiko ;

Nakajima, Go ;

Kamikozuru, Hirotaka ;

Yamamoto, Masakazu ;

Danenberg, Kathleen D. ;

Danenberg, Peter V. .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 65 (05) :825-831

[49] Epidermal growth factor receptor (EGFR) mRNA levels and protein expression levels in primary colorectal cancer and corresponding liver metastases [J].

Hidekazu Kuramochi ;

Kazuhiko Hayashi ;

Go Nakajima ;

Hirotaka Kamikozuru ;

Masakazu Yamamoto ;

Kathleen D. Danenberg ;

Peter V. Danenberg .

Cancer Chemotherapy and Pharmacology, 2010, 65 :825-831

[50] Amphiregulin and Epiregulin mRNA expression in primary colorectal cancer and corresponding liver metastases [J].

Hidekazu Kuramochi ;

Go Nakajima ;

Yuka Kaneko ;

Ayako Nakamura ;

Yuji Inoue ;

Masakazu Yamamoto ;

Kazuhiko Hayashi .

BMC Cancer, 12

← 1 2 3 4 5 →